RJA
VYGR icon

Raymond James & Associates’s Voyager Therapeutics VYGR Stock Holding History

Raymond James & Associates’s Portfolio VYGR Stock Details VYGR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-109,910
Closed -$670K – 4095
2022
Q4 		$670K Buy
+109,910
New +$625K ﹤0.01% 2682
2021
Q1 		– Sell
-12,244
Closed -$88K – 4118
2020
Q4 		$88K Sell
12,244
-5,650
-32% -$54.3K ﹤0.01% 3575
2020
Q3 		$191K Buy
17,894
+1,142
+7% +$13.4K ﹤0.01% 3232
2020
Q2 		$211K Buy
16,752
+658
+4% +$7.65K ﹤0.01% 3097
2020
Q1 		$147K Buy
16,094
+1,822
+13% +$20.9K ﹤0.01% 3129
2019
Q4 		$199K Sell
14,272
-12,044
-46% -$175K ﹤0.01% 3349
2019
Q3 		$453K Buy
26,316
+14,988
+132% +$315K ﹤0.01% 2715
2019
Q2 		$308K Sell
11,328
-4,187
-27% -$95.8K ﹤0.01% 3000
2019
Q1 		$297K Buy
+15,515
New +$202K ﹤0.01% 2988

Other funds holding VYGR

EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
EAM
Erste Asset Management Vienna, Austria $10.8B AUM 38.54% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Raymond James & Associates's VYGR Position: Q1 2023 in Review

Raymond James & Associates sold out of Voyager Therapeutics (VYGR) in Q1 2023, closing a stake of 109,910 shares — an estimated $670K sold.

Raymond James & Associates first reported a position in VYGR in Q1 2019 and held it in 9 quarters. The position peaked at $670K in Q4 2022. 81 funds tracked by Wall St. Rank hold VYGR as of Q1 2023.

  • Raymond James & Associates reported no remaining Voyager Therapeutics position as of Q1 2023 after selling out during the quarter.
  • Raymond James & Associates sold 109,910 Voyager Therapeutics shares in Q1 2023, an estimated $670K.
  • Raymond James & Associates first reported a position in Voyager Therapeutics in Q1 2019 and held it in 9 quarters.
  • Raymond James & Associates's Voyager Therapeutics position peaked at $670K in Q4 2022.
  • 81 funds tracked by Wall St. Rank held Voyager Therapeutics as of Q1 2023.

Based on Raymond James & Associates's 13F filing for Q1 2023, filed 14 Apr 2023.